pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Cancer Program
drug · antibody
save

Cancer Program

Phase 2updated 7mo ago
by Mirror Biologics Inc🔗 ChEMBL
Phase 2
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval256 co-mentions · 128 sources
  • drugpembrolizumab256 co-mentions · 128 sources
  • drugKEYTRUDA256 co-mentions · 128 sources
  • drugKEYTRUDA QLEX133 co-mentions · 128 sources
  • drug(berahyaluronidase alfa + pembrolizumab)5 co-mentions · 5 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 9 approved and 146 investigational indications.

targets

Programmed cell death protein 1

all catalysts(0)

nothing on the calendar yet

News(10)

  • Merck gets another Phase 3 win for sac-TMT, this time in gastric cancer
    An experimental antibody-drug conjugate from Merck has succeeded in another Phase 3 cancer study, potentially helping offset Keytruda's looming patent cliff. Merck said Friday morning that a pivota…
    endpoints · 17h ago
  • Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial
    Licensed from Kelun-Biotech, Merck’s TROP2-targeting antibody drug conjugate sac-TMT improved overall survival in advanced gastroesophageal cancer while missing on two secondary endpoints.
    biospace · 18h ago
  • Merck-Kelun ADC scores survival win in Phase 3 stomach cancer trial
    Licensed from Kelun-Biotech, Merck’s TROP2-targeting antibody drug conjugate sac-TMT improved overall survival in advanced gastroesophageal cancer while missing on two secondary endpoints.
    biospace · 18h ago
  • This week in charts: Biotech investors’ China bets are already paying off
    This year, companies built around medicines from China have sped toward acquisitions or IPOs. Meanwhile, Summit is no longer the Wall Street darling it was in 2024.
    biopharma_dive · 20h ago
  • Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
    Merck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.
    biospace · 2d ago
  • Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
    Summit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population.
    biospace · 2d ago
  • Sellas marks 9-month survival benefit in late-stage leukemia vaccine study
    Sellas Life Sciences’ cancer vaccine for acute myeloid leukemia has passed a phase 3 test with a more than nine-month improvement in overall survival.
    fiercebiotech · 4d ago
  • Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
    The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.
    biopharma_dive · 4d ago
  • Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer work
    Eli Lilly's business development team has inked 14 buyouts this year so far, with Calytrix Bio tucking into the pharma’s oncology pipeline.
    biospace · 4d ago
  • Summit's PD-1xVEGF rejected by FDA in lung cancer
    The FDA has denied an approval for Summit Therapeutics’ ivonescimab to treat EGFR-mutated non-small cell lung cancer, blocking the drug’s entry to the U.S. after it became available in China in 2024.
    biospace · 5d ago
view all news mentions →
trade names
Keytruda, Pembrolizumab component of mk 7684a, Pembrolizumab component of mk-1308a
MOA
Programmed cell death protein 1 inhibitor
indication
Metastatic Colorectal Cancer
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?